UNDERSTANDING RESTLESS LEG SYNDROME
RESTLESS LEG SYNDROME NASAL SWAB STUDY
Join our observational study to explore how prolonged use of dopamine agonists affects gene expression in RLS. By participating, you'll help us uncover insights into treatment-induced changes that could enhance future therapies. Eligible participants receive a $25 Amazon gift card for their time.
About this study
✅ Observational Study
If you are eligible, you will not be asked to make any changes to your current daily routine. You will be invited to self-administer a nasal swab at home, and return it to the research team.
🎁 Participant Compensation Available
Participants that complete all required study tasks will receive a $25 Amazon gift card.
🤳 Virtual Study
Participate from the comfort of your home from your own smartphone or computer.
What's Involved
- Verify Eligibility and Enroll: Sign up through our online platform and complete a short screening to confirm eligibility for the study. You will be asked to verify your RLS diagnosis prior to enrollment.
- Nasal Swab: Participants will be asked to self-administer a nasal swab that will be mailed to them, and use a return label to return it to the research team within 24 hours.
- Complete the Study: Participants who fulfill all study requirements will be able to download their personal study data via the Alethios platform once all participants have completed the study. Compensation will be provided at the end of the study period.
What's being studied?
This study by HBC Immunology, Inc. examines how long-term dopamine agonist treatment affects gene expression in individuals with RLS. While dopamine agonists manage symptoms, extended use may cause Augmentation Syndrome (AS), where symptoms worsen. By analyzing gene expression changes, this study aims to improve RLS treatment.
More about this study
For detailed study information, see the ClinicalTrials.gov listing at this link or contact the study investigator directly via support@alethios.com.
Am I eligible?
If you are a healthy adult between the ages of 18 and 76, have been either doctor-diagnosed with Restless Leg Syndrome (RLS), and are currently taking a dopamine agonist, such as (e.g. Pramipexole)you may qualify for this study.